Literature DB >> 16099151

Elevated levels of natriuretic peptides in patients with pulmonary thromboembolism.

David G Kiely1, Norman S Kennedy, Omar Pirzada, Sheila A Batchelor, Allan D Struthers, Brian J Lipworth.   

Abstract

BACKGROUND: Pulmonary thromboembolism (PTE) occurs in a wide variety of clinical settings and presents a diagnostic challenge to clinicians, often requiring extensive imaging of the vascular bed. Management increasingly requires accurate risk stratification to rapidly identify those with massive and submassive PTE requiring different therapeutic strategies such as thrombolysis. Provision of a rapid blood test that improves diagnostic certainty and helps stratify risk could therefore bridge the gap between uncertainty and delivery of immediate early life-saving treatment. METHODS AND
RESULTS: One hundred and fourteen consecutive patients with suspected PTE underwent prospective evaluation. Venous blood samples were obtained from an unselected group referred for ventilation-perfusion scintigraphy. B-type natriuretic peptide (BNP), atrial natriuretic peptide (ANP) and N-terminal pro-ANP (N-ANP) were measured by radioimmunoassay using commercially available kits. The scans were classified into three groups according to standard criteria (PIOPED); normal scan (N) (n=20), low/intermediate probability (L/I) of PTE (n=77) and high probability (H) of PTE (n=17). Comparisons were also made between patients with high probability scans who died (n=3) and those who survived (n=14). Values are quoted for the median and interquartile ranges. There were statistically significant differences between groups for levels of (a) BNP (P<0.001): N=6.7 pmol/l (5.6-11.9), L/I=12.5 pmol/l (6.7-28.2) and H=18.5 pmol/l (12.6-74.6); (b) ANP (P<0.005): N=12.6 pmol/l (7.1-16.0), L/I=19.51 pmol/l (12.5-28.2) and H=19.1 pmol/l (15.7-31.7) and (c) N-ANP (P<0.05): N=177 pmol/l (119-200), L/I=302 pmol/l (152-576) and H=322 pmol/l (223-563). Levels of BNP and ANP were significantly (P<0.05) higher in patients with high probability scans and a diagnosis of PTE who died (n=3) than in those who survived (n=14); BNP: 91.6 pmol/l (77.5-336.2) vs. 14.4 pmol/l (11.9-27.4) and ANP 32.5 pmol/l (21.7-105.5) vs. 17.6 pmol/l (15.2-19.3), respectively.
CONCLUSIONS: PTE is associated with significantly elevated levels of the natriuretic peptides ANP, BNP and N-ANP. Increasing ventilation-perfusion mismatch on scintigraphy corresponds to incremental increases in the levels of ANP, BNP and N-ANP found. These peptides, and in particular BNP, may add to the diagnosis by rapidly providing a probability of PE before dedicated imaging studies can be performed. Natriuretic peptides require further study to establish their role in identifying a high-risk group who may benefit from early treatments such as thrombolysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099151     DOI: 10.1016/j.rmed.2005.02.029

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

1.  Gene expression of ANP, BNP and ET-1 in the heart of rats during pulmonary embolism.

Authors:  Henrik Gutte; Jytte Oxbøl; Ulrik Sloth Kristoffersen; Jann Mortensen; Andreas Kjaer
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

2.  MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.

Authors:  Lars Heining; Christian Giesa; Santiago Ewig
Journal:  Lung       Date:  2016-01-09       Impact factor: 2.584

Review 3.  Natriuretic peptides in acute pulmonary embolism: a systematic review.

Authors:  Rodrigo Cavallazzi; Abhilash Nair; Tajender Vasu; Paul E Marik
Journal:  Intensive Care Med       Date:  2008-07-15       Impact factor: 17.440

4.  Serum levels of natriuretic peptides in patients with Behcet's disease.

Authors:  Ramazan Yağci; Yüksel Totan; Ekin Ozlük; Hüseyin Ozyurt; Gülfer Akbay; Meral Ekşioğlu
Journal:  Clin Rheumatol       Date:  2008-04-15       Impact factor: 2.980

5.  MR-proADM and MR-proANP levels in patients with acute pulmonary embolism.

Authors:  Önsel Öner; Figen Deveci; Selda Telo; Mutlu Kuluöztürk; Mehmet Balin
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

6.  Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH.

Authors:  Steffen D Kriechbaum; Lillith Scherwitz; Christoph B Wiedenroth; Felix Rudolph; Jan-Sebastian Wolter; Moritz Haas; Ulrich Fischer-Rasokat; Andreas Rolf; Christian W Hamm; Eckhard Mayer; Stefan Guth; Till Keller; Stavros V Konstantinides; Mareike Lankeit; Christoph Liebetrau
Journal:  ERJ Open Res       Date:  2020-11-02

Review 7.  Prognostic stratification of acute pulmonary embolism: focus on clinical aspects, imaging, and biomarkers.

Authors:  Luca Masotti; Marc Righini; Nicolas Vuilleumier; Fabio Antonelli; Giancarlo Landini; Roberto Cappelli; Patrick Ray
Journal:  Vasc Health Risk Manag       Date:  2009-07-14

Review 8.  Biomarkers in community-acquired pneumonia: a state-of-the-art review.

Authors:  Renato Seligman; Luis Francisco Ramos-Lima; Vivian do Amaral Oliveira; Carina Sanvicente; Elyara F Pacheco; Karoline Dalla Rosa
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

Review 9.  Acute pulmonary embolism multimodality imaging prior to endovascular therapy.

Authors:  David Sin; Gordon McLennan; Fabian Rengier; Ihab Haddadin; Gustavo A Heresi; John R Bartholomew; Matthias A Fink; Dustin Thompson; Sasan Partovi
Journal:  Int J Cardiovasc Imaging       Date:  2020-08-30       Impact factor: 2.357

10.  Prognostic value of right atrial dilation in patients with pulmonary embolism.

Authors:  Markus H Lerchbaumer; Matthias Ebner; Christian O Ritter; Laura Steimke; Nina I J Rogge; Carmen Sentler; Aaron Thielmann; Lukas Hobohm; Karsten Keller; Joachim Lotz; Gerd Hasenfuß; Rolf Wachter; Bernd Hamm; Stavros V Konstantinides; Galit Aviram; Mareike Lankeit
Journal:  ERJ Open Res       Date:  2021-05-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.